Inzirqo is a drug owned by Novitium Pharma Llc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 23, 2044. Details of Inzirqo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11878022 | Hydrochlorothiazide compositions |
Jan, 2044
(18 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Inzirqo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Inzirqo's family patents as well as insights into ongoing legal events on those patents.
Inzirqo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Inzirqo's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 23, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Inzirqo Generic API suppliers:
Hydrochlorothiazide is the generic name for the brand Inzirqo. 47 different companies have already filed for the generic of Inzirqo, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Inzirqo's generic
Alternative Brands for Inzirqo
There are several other brand drugs using the same active ingredient (Hydrochlorothiazide) as Inzirqo. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Abbvie |
| |||
| Ani Pharms |
| |||
| Boehringer Ingelheim |
| |||
| Cosette |
| |||
| Noden Pharma |
| |||
| Novartis |
| |||
| Sanofi Aventis Us |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Hydrochlorothiazide, Inzirqo's active ingredient. Check the complete list of approved generic manufacturers for Inzirqo
About Inzirqo
Inzirqo is a drug owned by Novitium Pharma Llc. Inzirqo uses Hydrochlorothiazide as an active ingredient. Inzirqo was launched by Novitium Pharma in 2025.
Approval Date:
Inzirqo was approved by FDA for market use on 28 January, 2025.
Active Ingredient:
Inzirqo uses Hydrochlorothiazide as the active ingredient. Check out other Drugs and Companies using Hydrochlorothiazide ingredient
Dosage:
Inzirqo is available in for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML | FOR SUSPENSION | Prescription | ORAL |